Using a new drug to improve treatment for glioblastoma
Signature-guided treatment of GBM with neddylation inhibitor pevonedistat
This study is looking at how a drug called pevonedistat, when used with another drug called etoposide, can help people with recurrent glioblastoma by figuring out which patients are most likely to benefit from this combination based on their tumor's unique features.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10928779 on NIH RePORTER |
What this research studies
This research investigates the use of a drug called pevonedistat, which inhibits a specific protein degradation pathway that is overactive in glioblastoma (GBM). The study aims to identify molecular signatures that can predict which patients are most likely to benefit from this treatment, particularly in combination with another drug called etoposide. By focusing on these 'synergy signatures', the research seeks to guide patient enrollment in clinical trials, ensuring that the right patients receive the most effective therapies. The goal is to improve outcomes for patients with recurrent GBM by tailoring treatments based on their unique tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent glioblastoma, particularly those with specific genetic alterations such as PTEN deletions or mutations.
Not a fit: Patients with glioblastoma who do not have the targeted molecular signatures or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in using molecular signatures to guide treatment decisions in cancer therapy, suggesting that this approach could be effective.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Berens, Michael E. — Beckman Research Institute/city of Hope
- Study coordinator: Berens, Michael E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.